Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...

JPMorgan upgraded Recursion Pharmaceuticals (RXRX) to Overweight from Neutral with a price target of $11, up from $10. The firm says the company’s REC-4881 has shown “strong and durable” efficacy in ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

On a Tuesday at the end of last semester, I asked my first-year writing class how they were using AI in their courses. One of ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best NASDAQ stocks under $10 to buy. As of December 15, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has a ‘Hold’ or equivalent rating from ...

We might earn a commission if you make a purchase through one of the links. The McClatchy Commerce Content team, which is independent from our newsroom, oversees this content. This article has ...

TORONTO, Dec. 30, 2025 (GLOBE NEWSWIRE) — Partners Value Investments L.P. (the “Partnership”) (TSX VENTURE: PVF) announced today that it has received approval from the TSX Venture Exchange (the ...

His job is to reimagine the future of drugmaking using that similarly trendy branch of computer science, artificial ...

This calculator shows how inflation affects the purchasing power of money over time. The nominal value is what your investment will be worth in future dollars, while the real value shows what it will ...

Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...